Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AXS-14

Small molecule · developed by Axsome Therapeutics

Phase 3 Most advanced trial

AXSM Developer

1 Registered trials

What is AXS-14?

AXS-14 is an investigational small-molecule drug studied in Fibromyalgia.

At a glance

Drug type: Small molecule
Therapy area: Musculoskeletal
Developer: Axsome Therapeutics, Inc. (AXSM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07398417	Phase 3	Fibromyalgia	Recruiting	AXSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fibromyalgia

More from Axsome Therapeutics

AXS-07 FDA approved Dextromethorphan/Bupropion FDA approved Solriamfetol FDA approved AXS-02 Phase 3

Sources

ClinicalTrials.gov NCT07398417

Updated Oct 3, 2026. Something wrong or missing? Report it on the AXSM page.

Follow AXSM, the company behind AXS-14

See AXSM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AXSM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z